SonoVascular
Private Company
Funding information not available
Overview
SonoVascular is a clinical-stage medical device company pioneering an ultrasound and microbubble-enhanced approach to treating venous thromboembolism (VTE). Its core technology, the SonoThrombectomy™ Triple Action Clot Debulking Catheter System, is designed to disrupt the interventional VTE treatment market by offering a potentially superior alternative to current pharmacological thrombolysis and mechanical thrombectomy methods. The company has initiated first-in-human studies, secured strategic partnerships for microbubble supply, and completed an initial Series A financing round. With a seasoned leadership team and a prestigious scientific advisory board, SonoVascular is positioned to address a significant unmet need in cardiovascular care.
Technology Platform
Ultrasound-based therapeutic platform utilizing microbubble-mediated cavitation for mechanical clot debulking via a catheter system.
Opportunities
Risk Factors
Competitive Landscape
SonoVascular competes in the interventional VTE space against large-cap medtech companies like Boston Scientific (AngioJet, EKOS), Medtronic, and Philips, which offer pharmacomechanical and ultrasound-enhanced thrombolysis systems. Its primary differentiation is the purely mechanical, cavitation-based action aiming to eliminate drug-related bleeding risks and improve complete clot removal to prevent PTS.